Biotech · Private company · Sherman Oaks, CA, US
Trethera
Track this companyFree. Adds Trethera to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- TRE-515Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid TumorsPHASE1 · RECRUITING · started Sep 23, 2021ClinicalTrials.gov NCT05055609 · fetched Nov 12, 2026
NIH awards10
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's diseaseFiscal year 2026 · $897.3KNIH RePORTER 5R42DK138578-03 · fetched Nov 12, 2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus ErythematosusFiscal year 2026 · $995KNIH RePORTER 5R44AI188587-02 · fetched Nov 12, 2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumorsFiscal year 2026 · $1.2MNIH RePORTER 5R44CA302066-02 · fetched Nov 12, 2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus ErythematosusFiscal year 2025 · $995KNIH RePORTER 1R44AI188587-01A1 · fetched Nov 12, 2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumorsFiscal year 2025 · $1.2MNIH RePORTER 1R44CA302066-01 · fetched Nov 12, 2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancerFiscal year 2025 · $406.5KNIH RePORTER 1R44CA306475-01 · fetched Nov 12, 2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's diseaseFiscal year 2025 · $905.3KNIH RePORTER 2R42DK138578-02 · fetched Nov 12, 2026
- Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic NeuritisFiscal year 2025 · $622.4KNIH RePORTER 5R42EY034397-03 · fetched Nov 12, 2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)Fiscal year 2025 · $1MNIH RePORTER 5R44AI186534-02 · fetched Nov 12, 2026
- Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)Fiscal year 2024 · $1.1MNIH RePORTER 1R44AI186534-01 · fetched Nov 12, 2026